Gut bacterial tyrosine decarboxylases restrict levels
of levodopa in the treatment of Parkinson’s disease
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Introduction

Methods

Results

Parkinson’s disease is the second most common
neurodegenerative disorder, which is primarily treated by
levodopa (L-DOPA)1. Previous research has shown that
the microbiota-inhabiting human gut has a significant
impact on the health of the host and indicate that
microbiota have a crucial effect on many health and
diseased states2. Additionally, studies show that gut
microbiota can impact the efficacy of drug
pharmacokinetics and drug bioavailability3, 4. Previous
research supports investigation of mechanisms impacting
L-DOPA treatments in Parkinson’s disease because LDOPA varies in efficacy of relieving symptoms among
Parkinson’s patients5. Still to be determined is whether
inter-individual variations in gut microbiota composition
play a causative role in the variation of L-DOPA treatment
efficacy.

To investigate whether natural
variation of tyrosine decarboxylase
relative abundance in the gut could
interfere with L-DOPA uptake and
decarboxylation, human fecal
samples from Parkinson’s patients on
varying doses of L-DOPA/carbidopa,
and jejunal content samples from
rats on oral L-DOPA/carbidopa
administration, were employed and
tyrosine decarboxylase levels were
detected. All data were ranked from
low to high by tyrosine
decarboxylase level and linear
regression was performed with
automatic outlier detection using the
ROUT method in Graphpad Prism 7.
Statistical tests performed were
unpaired T-tests, 2-way-ANOVA
followed by a Fisher’s LSD test.

All p-values in the study were ≤ 0.05, indicating that the strength
of the evidence is high. The r-coefficient for the tdc abundance
and jejunal dopamine levels indicated the strongest positive
correlation, while tdc abundance and jejunal levodopa/carbidopa
levels or plasma levodopa/carbidopa levels both demonstrated
fairly strong negative correlations:
• tdc abundance and jejunal dopamine levels
• r = 0.78, P value 0.0001
• tdc abundance and jejunal levodopa/carbidopa levels
• r = -0.68, P value 0.021
• tdc abundance and plasma levodopa/carbidopa levels
• r = -0.57, P value 0.017

Tyrosine decarboxylase genes (tdc) are encoded in the
genome of several bacterial species in the genera
Lactobacillus and Enterococcus6. Tdc might have the
ability to decarboxylate L-DOPA to produce dopamine7,
interfering with its bioavailability for therapeutic use.

Purpose
The purpose of the study is
to analyze the effect of
levodopa-metabolizing
bacteria at it’s primary site
of absorption, the jejunum,
and further use this
information to understand
the variability in L-DOPA
dosage requirements for
individual treatment of Parkinson’s Disease.

Results
It was determined that the bacteria
of the upper small intestinal
converts levodopa to dopamine.
A higher relative abundance of
bacterial Tyrosine decarboxylase
genes (tdc) in stool samples of
Parkinson’s Disease patients
positively correlated with higher
daily levodopa/carbidopa dosage
requirement and duration of disease.

Human Fecal
Sample

• n = 10
• Parkinson’s patients on variable
doses of levodopa/carbidopa
treatment

Rat Jejunal
Content

• n = 25
• Wild-type Groningen rats
• treated with E. faecalis v583 cells
followed by levodopa/carbidopa
mixture

Analysis

• Quantitative PCR of tdc genes
performed on DNA extracted
from each human fecal sample &
rat jejunal content samples

Conclusions
The authors conclude that levodopa conversion by bacterial tdc in
the small intestine should be considered as a significant
explanatory factor for the increased levodopa/carbidopa dosage
regimen in a subset of Parkinson’s patients. Therefore, bacteria or
their encoded tdc gene may serve as a predictive biomarker to
stratify Parkinson’s patients for efficacy of levodopa treatment.
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